Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

The purpose of this study is to learn how well a combination of iparomlimab and tuvonralimab (QL1706), lenvatinib, radiotherapy, and hepatic arterial infusion chemotherapy (HAIC) works and how safe it is for people with hepatocellular carcinoma (HCC) that has grown into the portal vein, forming a portal vein tumor thrombus (PVTT). Participants will receive iparomlimab and tuvonralimab together with lenvatinib, radiotherapy directed at the portal vein tumor thrombus, and HAIC, which delivers chemotherapy directly through the hepatic artery. Researchers will evaluate how long the cancer remains

Trial Details

NCT ID
NCT07776080
Phase
PHASE2
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Status
RECRUITING
Cancer Type
Hepatocellular Carcinoma (HCC) Liver Cancer
Interventions
  • Iparomlimab and Tuvonralimab (QL1706)
  • Lenvatinib
  • Radiotherapy
  • hepatic arterial infusion chemotherapy (HAIC)
Locations (sample)
  • Wuhan, Hubei, China|30.58333,114.26667

Key Eligibility Criteria

  • Age ≥18 and ≤75 years at the time of signing informed consent.
  • Histologically or clinically confirmed hepatocellular carcinoma (HCC) according to the 2024 Chinese Guidelines for the Diagnosis and Treatment of P…
  • Radiologically confirmed portal vein tumor thrombus (PVTT), classified as Cheng type I-IV.
  • No prior systemic or local treatment directed at PVTT, including targeted therapy, immunotherapy, or systemic chemotherapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hepatocellular Carcinoma (HCC) Liver Cancer Trials on Trialify →